{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:13:56Z","timestamp":1790846036477,"version":"4.1.0"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T00:00:00Z","timestamp":1542585600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008672","name":"Wilhelm Sander-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005678","name":"Fondation Jos\u00e9 Carreras Pour la Lutte Contra la Leuc\u00e9mie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005678","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.02553","type":"journal-article","created":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T06:00:53Z","timestamp":1542607253000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":47,"title":["CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells"],"prefix":"10.3389","volume":"9","author":[{"given":"Kerstin","family":"Sch\u00fctze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Petry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Hambach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Fumey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levin","family":"Schriewer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"R\u00f6ckendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Menzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birte","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"Haag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catelijne","family":"Stortelers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bannas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"Koch-Nolte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,11,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1177\/1060028016642786","article-title":"Immunotherapy: A new approach to treating multiple myeloma with Daratumumab and Elotuzumab","volume":"50","author":"Afifi","year":"2016","journal-title":"Ann Pharmacother."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e451","DOI":"10.1038\/bcj.2016.53","article-title":"New investigational drugs with single-agent activity in multiple myeloma","volume":"6","author":"Rajan","year":"2016","journal-title":"Blood Cancer J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: back to the future","volume":"131","author":"van de Donk","year":"2018","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12389","article-title":"Monoclonal antibodies targeting CD38 in hematological malignancies and beyond","author":"van de Donk","year":"2016","journal-title":"Immunol Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3390\/cells4030520","article-title":"NAD(+)-Metabolizing Ectoenzymes in remodeling tumor-host interactions: the human myeloma model","volume":"4","author":"Horenstein","year":"2015","journal-title":"Cells"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e26246","DOI":"10.4161\/onci.26246","article-title":"A CD38\/CD203a\/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes","volume":"2","author":"Horenstein","year":"2013","journal-title":"Oncoimmunology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"25602","DOI":"10.18632\/oncotarget.4693","article-title":"A non-canonical adenosinergic pathway led by CD38 in human melanoma cells induces suppression of T cell proliferation","volume":"6","author":"Morandi","year":"2015","journal-title":"Oncotarget"},{"key":"B8","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.tips.2018.02.001","article-title":"The pharmacology of CD38\/NADase: an emerging target in cancer and diseases of aging","volume":"39","author":"Chini","year":"2018","journal-title":"Trends Pharmacol Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with Daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2015.01.028","article-title":"Complement in therapy and disease: regulating the complement system with antibody-based therapeutics","author":"Melis","year":"2015","journal-title":"Mol Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1056\/NEJM200104053441406","article-title":"Complement","volume":"344","author":"Walport","year":"2001","journal-title":". N Engl J Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1056\/NEJM200104123441506","article-title":"Complement","volume":"344","author":"Walport","year":"2001","journal-title":". N Engl J Med."},{"key":"B14","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.150.3695.505","article-title":"Complement fixation on cell surfaces by 19S and 7S antibodies","volume":"150","author":"Borsos","year":"1965","journal-title":"Science"},{"key":"B15","doi-asserted-by":"publisher","first-page":"4998","DOI":"10.1158\/0008-5472.CAN-07-6226","article-title":"Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies","volume":"68","author":"Dechant","year":"2008","journal-title":"Cancer Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1111\/j.1349-7006.2011.02019.x","article-title":"Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII)","volume":"102","author":"Klausz","year":"2011","journal-title":"Cancer Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3876","DOI":"10.1158\/0008-5472.CAN-05-3434","article-title":"Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma","volume":"66","author":"Macor","year":"2006","journal-title":"Cancer Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.1248943","article-title":"Complement is activated by IgG hexamers assembled at the cell surface","volume":"343","author":"Diebolder","year":"2014","journal-title":"Science"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e1002344","DOI":"10.1371\/journal.pbio.1002344","article-title":"A novel platform for the potentiation of therapeutic antibodies based on antigen-dependent formation of IgG Hexamers at the cell surface","volume":"14","author":"de Jong","year":"2016","journal-title":"PLoS Biol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1517\/14712598.5.1.111","article-title":"Nanobodies as novel agents for cancer therapy","volume":"5","author":"Revets","year":"2005","journal-title":"Expert Opin Biol Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00430-009-0116-7","article-title":"Single domain antibodies: promising experimental and therapeutic tools in infection and immunity","volume":"198","author":"Wesolowski","year":"2009","journal-title":"Med Microbiol Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","article-title":"Nanobodies: natural single-domain antibodies","volume":"82","author":"Muyldermans","year":"2013","journal-title":"Annu Rev Biochem"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/0471142735.im0217s103","article-title":"Single-domain antibodies and their utility","volume":"103","author":"Baral","year":"2013","journal-title":"Curr Protoc Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1146\/annurev-immunol-042617-053327","article-title":"Exploiting nanobodies' singular traits","volume":"36","author":"Ingram","year":"2018","journal-title":"Annu Rev Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1002\/ijc.26145","article-title":"A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth","volume":"129","author":"Roovers","year":"2011","journal-title":"Int J Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"366ra162","DOI":"10.1126\/scitranslmed.aaf8463","article-title":"Nanobodies that block gating of the P2X7 ion channel ameliorate inflammation","volume":"8","author":"Danquah","year":"2016","journal-title":"Sci Transl Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1158\/1535-7163.MCT-07-2384","article-title":"Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology","volume":"7","author":"Tijink","year":"2008","journal-title":"Mol Cancer Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"4764","DOI":"10.1096\/fj.14-253369","article-title":"A novel platform for engineering blood-brain barrier-crossing bispecific biologics","volume":"28","author":"Farrington","year":"2014","journal-title":"FASEB J."},{"key":"B29","doi-asserted-by":"publisher","first-page":"27055","DOI":"10.1038\/srep27055","article-title":"Immuno-targeting the multifunctional CD38 using nanobody","volume":"6","author":"Li","year":"2016","journal-title":"Sci Rep."},{"key":"B30","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/nchem.2811","article-title":"Cell-permeable nanobodies for targeted immunolabelling and antigen manipulation in living cells","volume":"9","author":"Herce","year":"2017","journal-title":"Nat Chem."},{"key":"B31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.pep.2016.03.004","article-title":"Construction and expression of an anti-VEGFR2 Nanobody-Fc fusionbody in NS0 host cell","volume":"123","author":"Qasemi","year":"2016","journal-title":"Protein Expr Purif."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.3389\/fimmu.2017.01603","article-title":"Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics","volume":"8","author":"Bannas","year":"2017","journal-title":"Front Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1073\/pnas.1801524115","article-title":"Anti-CTLA-4 therapy requires an Fc domain for efficacy","volume":"115","author":"Ingram","year":"2018","journal-title":"Proc Natl Acad Sci USA."},{"key":"B34","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired Thrombotic Thrombocytopenic Purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1111\/jth.13716","article-title":"Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura","volume":"15","author":"Peyvandi","year":"2017","journal-title":"J Thromb Haemost."},{"key":"B36","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.pharmthera.2016.06.012","article-title":"Nanobodies(R) as inhaled biotherapeutics for lung diseases","volume":"169","author":"Van Heeke","year":"2017","journal-title":"Pharmacol Ther."},{"key":"B37","volume-title":"Cablivi (caplacizumab). An Overview of Cablivi and Why It Is Authorized in the EU. EMA\/462233\/2018","year":"2018"},{"key":"B38","doi-asserted-by":"publisher","first-page":"14289","DOI":"10.1038\/s41598-017-14112-6","article-title":"Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38(+) tumors in mouse models in vivo","volume":"7","author":"Fumey","year":"2017","journal-title":"Sci Rep."},{"key":"B39","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/363446a0","article-title":"Naturally occurring antibodies devoid of light chains","volume":"363","author":"Hamers-Casterman","year":"1993","journal-title":"Nature"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2015.01.003","article-title":"Alternative molecular formats and therapeutic applications for bispecific antibodies","author":"Spiess","year":"2015","journal-title":"Mol Immunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"5145","DOI":"10.1073\/pnas.1220145110","article-title":"Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange","volume":"110","author":"Labrijn","year":"2013","journal-title":"Proc Natl Acad Sci USA."},{"key":"B42","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/nbt.2797","article-title":"Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface","volume":"32","author":"Lewis","year":"2014","journal-title":"Nat Biotechnol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"7535","DOI":"10.1074\/jbc.M114.620260","article-title":"A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism","volume":"290","author":"Liu","year":"2015","journal-title":"J Biol Chem."},{"key":"B44","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/1472-6750-13-52","article-title":"High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells","volume":"13","author":"Jager","year":"2013","journal-title":"BMC Biotechnol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.pep.2008.10.011","article-title":"Transient expression and purification of chimeric heavy chain antibodies","volume":"65","author":"Zhang","year":"2009","journal-title":"Protein Expr Purif."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02553\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T06:00:55Z","timestamp":1542607255000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02553\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,19]]},"references-count":47,"alternative-id":["10.3389\/fimmu.2018.02553"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.02553","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,19]]},"article-number":"2553"}}